Citable company snapshot

MRNA financial facts from SEC filings

Server-rendered

Moderna, Inc.'s latest SEC-sourced 2026-06-30 period shows $145.00M in revenue and $-782.00M in net income.

MRNA financial facts from SEC filings
MetricLatest periodLatest valuePrior valueYoY
RevenueJun 30, 2026$145.00M$389.00M-62.7%
Operating IncomeJun 30, 2026$-815.00M$-1.39B+41.3%
Net IncomeJun 30, 2026$-782.00M$-1.34B+41.8%
Operating Cash Flow (computed)Jun 30, 2026$-526.00M$-630.00M+16.5%
Free Cash Flow (computed)Jun 30, 2026$-563.00M$-692.00M+18.6%

Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Jul 31, 2026; accession 0001682852-26-000150.

Sign in to continue

MRNA company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.

New here? See what Pro includes →